Research Article
Role of p73 Dinucleotide Polymorphism in Prostate Cancer and p73 Protein Isoform Balance
Table 4
Summary of association studies of p73 DNP in various cancer sites1.
| Site | Population | Case/control | OR (95% CI) | Reference |
| Bladder | Indian | 200/200 | 1.54 (1.02–2.33) | [6] |
| Breast | Chinese | 170/178 | 0.77 (0.50–1.19) | [7] | Breast | Chinese | 170/0 | 2.76 | [8] | Breast | Japanese | 200/282 | 0.82 (0.57–1.19) | [9] | Breast | France white | 59/34 | 2.46 (0.92–6.58) | [10] |
| Cervical | Portuguese | 176/141 | 1.01 (0.63–1.62) | [11] | Cervical | Japanese | 112/442 | 1.51 (1.00–2.30) | [12] |
| Colorectal | Japanese | 147/235 | 0.85 (0.56–1.29) | [13] | Colorectal | Tunisian | 150/204 | 1.09 (0.71–1.66) | [14] | Colorectal | Korean | 383/469 | 1.50 (1.14–1.96) | [15] | Colorectal | Swedish | 179/260 | 0.92 (0.53–1.53) | [16] |
| Endometrial | Japanese | 114/442 | 1.36 (0.90–2.06) | [17] |
| Esophageal | Chinese | 348/630 | 1.02 (0.78–1.34) | [18] | Esophageal | Japanese | 102/235 | 0.64 (0.40–1.04) | [13] | Esophageal | UK whites | 84/152 | 0.90 (0.53–1.53) | [19] | H&N | US white | 708/1229 | 1.31 (1.09–1.58) | [20] | H&N | Italian | 283/295 | 1.36 (0.95–1.93) | [21] | H&N | US whites | 326/349 | 1.06 (0.78–1.45) | [22] | Oral | Indian | 303/319 | 2.38 (1.73–3.29) | [23] | Oropharyngeal | US mixed | 309/0 | 2.10 | [24] |
| Gastric | Italian | 114/295 | 0.94 (0.58–1.54) | [25] | Gastric | Japanese | 144/235 | 0.88 (0.58–1.34) | [13] |
| Liver | Chinese | 476/526 | 2.19 | [26] |
| Lung | Chinese | 293/380 | 1.48 (1.08–2.02) | [27] | Lung | US white | 1054/1139 | 1.34 (1.13–1.59) | [28] | Lung | Chinese | 425/588 | 0.67 (0.52–0.86) | [29] | Lung | Korean | 582/582 | 1.13 (0.90–1.43) | [30, 31] | Lung | US white | 863/852 | 1.34 (1.10–1.64) | [32] | Lung | Japanese | 189/235 | 0.91 (0.62–1.34) | [33] |
| Lymphoma | Japanese | 103/440 | 1.61 (1.04–2.47) | [34] |
| Melanoma | Whites | 805/838 | 1.05 (0.86–1.28) | [35] |
| Ovary | Chinese | 257/257 | 0.81 (0.95–1.18) | [36] |
| Prostate | Indian | 177/265 | 1.21 (0.80–1.86) | [37] |
|
|
Analysis is based on dominant model (AT/AT + GC/AT versus GC/GC).
2Cases only.
3HPV16+ versus HPV16−.
4HbsAg-positive individuals.
|